Pioneering a paradigm shift in treating Alzheimer's and Parkinson's through neuropeptide preservation and replacement.
Peer-reviewed funding from two of the world’s leading dementia research organisations — validation of our scientific approach as we head into human trials.
Even drugs that successfully reduced plaques by nearly 70% showed no cognitive improvement — and direct amyloid blocking drugs actually accelerated decline.
The breakthrough insight: Alzheimer's and Parkinson's are driven by neuropeptide depletion, not accumulation. When soluble neuropeptide levels fall below a critical threshold, synapses fail and cognition collapses.
We restore what the brain needs.
Neuropep Therapeutics focuses on restoring synaptic function and recovering memory formation via two complementary approaches: protection of endogenous peptides in the CSF, and replacement via stable peptide analogues.
The brain isn't poisoned.
It's starving.
Three decades. More than a thousand trials. Over forty billion dollars. The field's single most-funded idea produced a best-in-class result that no clinician can perceive at the bedside, and left the mechanism the human data actually implicates almost entirely unexplored.
Anti-amyloid clearance is not under-explored. It is the most expensively tested hypothesis in the history of neurodegeneration. Its best outcome to date is a 0.45-point slowing of decline over eighteen months, below the threshold a physician can detect in an individual patient. The capital that chased it has earned effectively zero disease-modifying cures.
Our lead candidate is a novel single-drug formulation built on a pathway with an established human safety record, which collapses early-stage clinical risk and compresses the timeline that makes conventional neuro-drug development a decade-long gamble. Non-dilutive grant capital from two of the world's leading dementia charities has already funded the trial.
Nearly every competitor differentiates on how it clears aggregates. We differentiate on what we target. In a field this saturated, addressing an entirely different mechanism is the moat.
Regulatory rejections across Europe and the UK, a sweeping Cochrane review, and mounting skepticism from within the field itself mean the capital that pursued amyloid is actively seeking its next thesis. No other clinical-stage program is positioned on the depletion branch.
The field spent thirty years and forty billion dollars proving where the answer is not. That work is done, and it points in one direction.
Addressing neurodegeneration at multiple stages — from prevention to potential reversal.
A novel oral monotherapy formulation — first to market for this specific approach — protecting endogenous neuropeptides from degradation. Derived from an FDA-approved therapeutic with established safety profile, our proprietary formulation represents new intellectual property with a de-risked development pathway.
Second-generation non-aggregating peptide analogues with novel structural modifications, enhanced brain penetration, and optimized stability. Neuropep Therapeutics is racing to become the first company to deliver a curative neuropeptide replacement therapy — safe, non-aggregating analogues that directly restore the synaptic function lost in Alzheimer's and Parkinson's disease.
Independent experts in Alzheimer's, Parkinson's, clinical informatics, and patient advocacy providing rigorous external validation of our platform thesis.
For investment inquiries and partnership opportunities. We welcome conversations with accredited investors at all stages.